Drugs Information:
Enfortumab vedotin
Basic Information
|
||
| ID | DDInter642 | |
| Drug Type | biotech | |
| Protein Chemical Formula | None | |
| Protein Average Weight | 152000.000 | |
| CAS Number | 1346452-25-2 | |
| Description | Enfortumab vedotin is an antibody-drug conjugate used in the treatment of patients with advanced, treatment-resistant urothelial cancers.[L10836] It is comprised of a fully human monoclonal antibody targeted against Nectin-4 and a microtubule-disrupting chemotherapeutic agent, monomethyl auristatin E (MMAE), joined by a protease-cleavable link.[L10836] It is similar to [brentuximab vedotin], another antibody conjugated with MMAE that targets CD-30 instead of Nectin-4. The clinical development of enfortumab vedotin was the result of a collaboration between Astellas Pharma and Seattle Genetics [A188868] and it was first approved for use in the United States in December 2019 under the brand name PadcevTM.[L10836] Enfortumab vedotin was later approved by the European Commission on April 13, 2022.[L42000] | |
| ATC Classification | L01FX13 | |
| Sequences | None | |
| Useful Links | DrugBank PubChem Substance Wikipedia | |
Interactions with
Enfortumab vedotin
Filter:
| Severity level | ID | Name | Mechanism | Detail |
|---|
Interactions with diseases
Filter:
| Severity level | Disease name | Text | References |
|---|
Interactions with foods
Filter:
| Severity level | Food name | Description | Management | Mechanism | References |
|---|
Interactions with compound preparation
| Multi-DRUG trade | Multi-DRUG | Drug type | Warning | Note |
|---|